Last reviewed 2026-05-16 · How we verify

COMIRNATY intramuscular injection (comirnaty-intramuscular-injection)

COMIRNATY is a COVID-19 vaccine developed by Pfizer Inc. It works by instructing cells in the body to produce a protein from the SARS-CoV-2 virus, which triggers an immune response. The vaccine is administered intramuscularly and is approved for individuals 6 months of age and older. It is particularly recommended for those with certain heart conditions or weakened immune systems. COMIRNATY has generated significant revenue, with $63.6 billion in sales. The vaccine's mechanism of action and broad indications have made it a crucial tool in the fight against COVID-19. Its commercial success has also driven further pipeline developments.

At a glance

Approved indications

• Prevention of COVID-19 in individuals 6 months of age and older
• Prevention of COVID-19 in individuals 5 years of age and older
• Prevention of COVID-19 in individuals 12 years of age and older
• Prevention of COVID-19 in individuals 6 months of age and older with certain kinds of heart disease, such as heart failure, coronary artery disease, and hypertension
• Prevention of COVID-19 in individuals 6 months of age and older with weakened immune systems, such as people with conditions or taking medications that weaken the immune system
• Prevention of COVID-19 in individuals 6 months of age and older with lung disease, such as chronic obstructive pulmonary disease (COPD) and asthma
• Prevention of COVID-19 in individuals 6 months of age and older with type 1 diabetes
• Prevention of COVID-19 in individuals 6 months of age and older with obesity
• Prevention of COVID-19 in individuals 6 months of age and older with neurologic conditions such as dementia
• Prevention of COVID-19 in individuals 6 months of age and older with pregnancy
• Prevention of COVID-19 in individuals 6 months of age and older with HIV infection
• Prevention of COVID-19 in individuals 6 months of age and older with chronic kidney disease
• Prevention of COVID-19 in individuals 6 months of age and older with sickle cell disease
• Prevention of COVID-19 in individuals 6 months of age and older with cerebral palsy
• Prevention of COVID-19 in individuals 6 months of age and older with Down syndrome
• Prevention of COVID-19 in individuals 6 months of age and older with Turner syndrome
• Prevention of COVID-19 in individuals 6 months of age and older with other health conditions or factors that increase the risk of severe illness
• Prevention of COVID-19 in individuals 5 years of age and older with certain kinds of heart disease, such as heart failure, coronary artery disease, and hypertension
• Prevention of COVID-19 in individuals 5 years of age and older with weakened immune systems, such as people with conditions or taking medications that weaken the immune system
• Prevention of COVID-19 in individuals 5 years of age and older with lung disease, such as chronic obstructive pulmonary disease (COPD) and asthma

Common side effects

No common side effects on file.

Drug interactions

• Live vaccines
• Interferon-alpha
• Interferon-beta
• Interferon-gamma
• Live vaccines
• Interferon-alpha
• Interferon-beta
• Interferon-gamma
• Live vaccines
• Interferon-alpha
• Interferon-beta
• Interferon-gamma

Key clinical trials

• Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study) (PHASE4)
• A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults. (PHASE1, PHASE2)
• Korea Comirnaty Post-marketing Surveillance
• Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults (PHASE1, PHASE2)
• A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults (PHASE2)
• A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection (PHASE2)
• Anti-viral Action Against Type 1 Diabetes Autoimmunity (PHASE4)
• Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• COMIRNATY intramuscular injection CI brief — competitive landscape report
• COMIRNATY intramuscular injection updates RSS · CI watch RSS
• Pfizer portfolio CI